GlycoMimetics Presents Data on Its E-Selectin Antagonist at American Association for Cancer Research Annual Meeting 2014

- Data on GMI-1271 highlighted with three posters -

Business Wire

GAITHERSBURG, Md.--(BUSINESS WIRE)--

GlycoMimetics, Inc. (GLYC) announced today that three posters of preclinical research study data for its E-Selectin antagonist (GMI-1271) were highlighted at the American Association for Cancer Research (AACR) Annual Meeting 2014. GlycoMimetics is initially exploring the clinical use of the drug to treat acute myeloid leukemia (AML). The company plans to initiate a Phase 1 trial of GMI-1271 in healthy volunteers during the second quarter of 2014.

Posters presented at the AACR meeting highlighted the novel drug candidate’s potential in improving chemotherapy treatment, as well as in advancing treatments in solid tumors and hematological cancers. Two posters “Exploration of a Potent E-selectin Antagonist (GMI-1271) As a Potential Novel Therapeutic for Treating Breast Cancer Metastasis to the Bone and Lung,” and “Breast Cancer Cells Metastasize to Bone Through E-selectin+ Vascular Gateways,” focused on targeting early steps involved with metastasis and the drug’s potential role in reducing binding of breast cancer cells and E-selectin. A third poster, “A Small Molecule Glycomimetic Antagonist of E-selectin (GMI-1271) Prevents Pancreatic Tumor Metastasis and Offers a Novel Treatment for Improved Efficacy of Chemotherapy,” highlighted the potential role of GMI-1271 in improving standard chemotherapy by preventing pancreatic tumor cell entry into the blood and lymphatic systems.

“As we prepare to move into clinical studies with our GMI-1271 program, the AACR Annual Meeting 2014 offers a great opportunity for us to present our preclinical research findings to the cancer research community,” said John Magnani, Ph.D., GlycoMimetics Vice President and Chief Scientific Officer. “We look forward to further exploring the drug candidate’s potential to help people living with blood cancers and solid tumor cancers that are at risk of metastasis.”

The meeting abstracts are available at AACR’s website at: http://www.abstractsonline.com/Plan/SSResults.aspx

About GlycoMimetics, Inc.
GlycoMimetics is a clinical stage biotechnology company focused on the discovery and development of novel glycomimetic drugs to address unmet medical needs resulting from diseases in which carbohydrate biology plays a key role. Glycomimetics are molecules that mimic the structure of carbohydrates involved in important biological processes. Using its expertise in carbohydrate chemistry and knowledge of carbohydrate biology, GlycoMimetics is developing a pipeline of glycomimetic drug candidates that inhibit disease-related functions of carbohydrates, such as the roles they play in inflammation, cancer and infection.

This press release contains forward-looking statements regarding GlycoMimetics’ planned activities with respect to the clinical development of GMI-1271 and other matters. Actual results may differ materially from those in these forward-looking statements. For a further description of the risks associated with these statements, as well as other risks facing GlycoMimetics, please see the risk factors described in the Company’s annual report on form 10-K that was filed with the U.S. Securities and Exchange Commission on March 31, 2014, and other filings the company makes with the SEC from time to time. Forward-looking statements speak only as of the date of this release, and GlycoMimetics undertakes no obligation to update or revise these statements, except as may be required by law.

Contact:
GlycoMimetics, Inc. (GMI)
Brian Hahn, 240-243-1207
bhahn@glycomimetics.com

Rates

View Comments (0)